Diabetes Unit, Endocrinology and Nutrition Department, Hospital Clínic de Barcelona, Barcelona, Spain.
Diabetes Unit, Endocrinology and Nutrition Department, Hospital Clínic de Barcelona, Barcelona, Spain.
Diabetes Res Clin Pract. 2021 Sep;179:109026. doi: 10.1016/j.diabres.2021.109026. Epub 2021 Aug 26.
Evaluate the weight trajectories after pancreas transplantation (PT) and their relationships with pancreas graft outcomes in type 1 diabetes (T1D).
Retrospective cohort study. T1D individuals who underwent PT were recruited (T1D-PT; n = 194) and divided into three groups according to transplantation date: 1999-2004 (n = 57), 2005-2009 (n = 79), 2010-2015 (n = 58). For weight comparisons, a random sample of T1D without renal impairment was also recruited during 2015 (n = 61; T1D-control).
The median follow-up for the T1D-PT group was 11.1 years. Despite significant weight loss at 6 months (65.7 ± 12.4 vs. 64.1 ± 11.4 Kg; p < 0.001), a stepped increase was seen thereafter (60 months: 68.0 ± 14.0 Kg; p < 0.001). Participants from the 2010-2015 period showed higher weight gain (p < 0.001), outweighing that observed in the T1D-control (60 months: +4.69 ± 8.49 vs. -0.97 ± 4.59 Kg; p = 0.003). Weight gain between 6 and 36 months was directly associated with fasting glucose and HbA1c at 36 months, and with HbA1c at 60 months (p < 0.05). However, in Cox-regression models adjusted for age, sex, and several recipient and PT-related variables, the third tertile of weight gain between 6 and 36 months showed a non-significant increase in the graft failure/dysfunction (HR 2.33 [0.75-7.27]).
Weight gain post-PT was associated with glucose-related biochemical markers of graft dysfunction, which needs confirmation in further studies.
评估 1 型糖尿病(T1D)患者胰腺移植(PT)后的体重轨迹及其与胰腺移植物结局的关系。
回顾性队列研究。招募接受 PT 的 T1D 个体(T1D-PT;n=194),并根据移植日期分为三组:1999-2004 年(n=57)、2005-2009 年(n=79)、2010-2015 年(n=58)。为了进行体重比较,在 2015 年还随机招募了一组无肾功能损害的 T1D 患者(n=61;T1D-对照组)。
T1D-PT 组的中位随访时间为 11.1 年。尽管在 6 个月时体重显著减轻(65.7±12.4 与 64.1±11.4 Kg;p<0.001),但此后体重逐渐增加(60 个月:68.0±14.0 Kg;p<0.001)。2010-2015 年期间的参与者体重增加更多(p<0.001),超过了 T1D-对照组(60 个月:+4.69±8.49 与-0.97±4.59 Kg;p=0.003)。6-36 个月期间的体重增加与 36 个月时的空腹血糖和 HbA1c 以及 60 个月时的 HbA1c 直接相关(p<0.05)。然而,在调整年龄、性别以及多个受者和 PT 相关变量的 Cox 回归模型中,6-36 个月期间体重增加的第三 tertile 与移植物功能障碍/衰竭的风险增加无关(HR 2.33[0.75-7.27])。
PT 后体重增加与与移植物功能障碍相关的葡萄糖相关生化标志物有关,这需要在进一步的研究中进行确认。